Moody’s Analytics Wins Best Vendor Solution for Transactional Reporting (AnaCredit) at RegTech Insight Awards
Moody’s Analytics, a global provider of financial intelligence, has won Best Vendor Solution for Transactional Reporting (AnaCredit) at the 2019 RegTech Insight Awards.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190516005883/en/
We earned this award for our Transactional Reporting Tool (TRT), part of the Moody’s Analytics Banking Cloud platform. Flexible and scalable, the TRT is our first native-SaaS regulatory reporting solution, combining award-winning Moody’s Analytics regulatory expertise with cloud-native technology.
Financial institutions in the eurozone use the TRT to generate AnaCredit reports required by the European Central Bank and National Central Banks. An end-to-end solution, the TRT lets firms control the entirety of their AnaCredit regulatory process, from data ingestion using big data technology to validation and submission of reports.
Firms using the TRT also benefit from its integration with another award-winning Moody’s Analytics solution, Bureau van Dijk’s Orbis . Data gaps, and the presence of poor-quality data, can pose significant challenges. The TRT draws from the Orbis database of more than 300 million companies to enrich counterparty data and identify discrepancies between an institution’s current attributes and those in the Orbis database.
“We’re honored to earn this recognition at the RegTech Insight Awards,” said Pierre-Etienne Chabanel, Managing Director at Moody’s Analytics. “Our clients’ needs are diverse and ever-changing. In a world where reporting is becoming much more granular, our award-winning solution helps banks use new technology to meet this challenge.”
This win in the RegTech Insight Awards adds to our growing list of awards and industry accolades.
About Moody’s Analytics
Moody’s Analytics provides financial intelligence and analytical tools to help business leaders make better, faster decisions. Our deep risk expertise, expansive information resources, and innovative application of technology help our clients confidently navigate an evolving marketplace. We are known for our industry-leading and award-winning solutions, made up of research, data, software, and professional services, assembled to deliver a seamless customer experience. We create confidence in thousands of organizations worldwide, with our commitment to excellence, open mindset approach, and focus on meeting customer needs. For more information about Moody’s Analytics, visit our website or connect with us on Twitter and LinkedIn .
Moody's Analytics, Inc. is a subsidiary of Moody's Corporation (NYSE: MCO). Moody’s Corporation reported revenue of $4.4 billion in 2018, employs approximately 13,200 people worldwide and maintains a presence in 42 countries.
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CELLTRION-HEALTHCARE29.5.2020 01:03:03 CEST | Press release
New data show first-line triplet regimen of pembrolizumab, Herzuma® (biosimilar trastuzumab) and chemotherapy are effective in treatment of HER2-positive advanced gastric cancer
TAKEDA-PHARMACEUTICAL29.5.2020 01:02:13 CEST | Press release
European Commission Releases Takeda From Commitment to Divest Shire’s Pipeline Compound SHP647
NY-JEFFERIES-FINANCIAL28.5.2020 18:04:07 CEST | Press release
Jefferies' Clients, Employees and Shareholders Contribute $9,250,000 to Over 85 Charities for Coronavirus Relief in Memory of Peg Broadbent
NY-JRJ-GROUP28.5.2020 15:32:10 CEST | Press release
JRJ Group Announces Sale of ETX Capital to Guru Capital
ELICHENS28.5.2020 15:02:11 CEST | Press release
eLichens Launches eStore for US and EU Markets
SD-SAB-BIOTHERAPEUTICS28.5.2020 14:26:07 CEST | Press release
SAB Biotherapeutics Confirms Neutralizing Antibodies to SARS-CoV-2 and Begins Clinical Manufacturing of Novel COVID-19 Therapeutic Candidate
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom